Kaiser Permanente-San Diego Mission
Kaiser Permanente-San Diego Mission
San Diego, California, United States24 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | Digestive System Diseases, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, adenocarcinoma, carcinoma, digestive system disorder, epithelial neoplasm, hypertrophic pyloric stenosis, mouth disorder, neoplasm, pyloric stenosis, salivary duct carcinoma, salivary gland basal cell adenocarcinoma, salivary gland cancer, salivary gland disorder, stomach disorder | Active, not recruiting | Phase 2 | 2026-10-07 | NCT02749903 | |
| Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Not stated | 2026-09-25 | NCT03516942 | |
| S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04071457 | |
| A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, liver lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04115631 | |
| Mobile Health for Adherence in Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-09-04 | NCT06112613 | |
| Breast Cancer WEight Loss Study (BWEL Study) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, skin disorder, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-09-02 | NCT02750826 | |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, embryonal carcinoma, immature ovarian teratoma, malignant germ cell tumor, mesonephric neoplasm, neoplasm, teratoma, yolk sac tumor | Recruiting | Phase 3 | 2026-08-25 | NCT03067181 | |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell acute lymphoblastic leukemia, Tumor Virus Infections, acute biphenotypic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mixed phenotype acute leukemia, neoplasm, viral infectious disease | Active, not recruiting | Phase 3 | 2026-08-21 | NCT05602194 | |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Metastatic Small Intestinal Adenocarcinoma; Stage III Small Intestinal Adenocarcinoma AJCC v8; Stage IIIA Small Intestinal Adenocarcinoma AJCC v8; Stage IIIB Small Intestinal Adenocarcinoma AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Recruiting | Phase 2 | 2026-08-20 | NCT04205968 | |
| Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Not applicable | 2026-08-06 | NCT03253848 | |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-07-08 | NCT03269669 | |
| Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT02193282 | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Adnexal Diseases, Bartholin gland transitional cell carcinoma, Biliary Tract Neoplasms, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Gestational Trophoblastic Disease, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Nose Neoplasms, Otorhinolaryngologic Neoplasms, Parathyroid Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Pregnancy Complications, Neoplastic, Rare Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, acinar cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, adrenal gland pheochromocytoma, angiosarcoma, apocrine sweat gland neoplasm, basal cell carcinoma, basal cell neoplasm, bile duct disorder, bile duct neoplasm, biliary tract disorder, bladder adenocarcinoma, carcinoma, carcinosarcoma, cervical adenocarcinoma, cholangiocarcinoma, chordoma, colorectal squamous cell carcinoma, connective tissue neoplasm, cystadenocarcinoma, cystic, mucinous, and serous neoplasm, desmoid tumor, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial transitional cell carcinoma, endometrium neoplasm, epithelial neoplasm, extrahepatic bile duct carcinoma, extramammary Paget disease, fallopian tube adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroma, fibromyxoid tumor, fibrosarcoma, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, gastric squamous cell carcinoma, gastrointestinal stromal tumor, germinoma, gestational trophoblastic neoplasm, gonadal disorder, intrahepatic cholangiocarcinoma, lung adenocarcinoma, lung giant cell carcinoma, lung neoplasm, lung neuroendocrine neoplasm, lung sarcomatoid carcinoma, major salivary gland carcinoma, malignant endocrine neoplasm, minimally invasive lung adenocarcinoma, mixed neoplasm, mouth disorder, mucinous adenocarcinoma, mucinous adenocarcinoma of the appendix, mucinous cystadenocarcinoma, nasal cavity adenocarcinoma, nasal cavity carcinoma, nasal disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, nerve sheath neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, oral cavity carcinoma, otorhinolaryngologic disease, ovarian adenocarcinoma, ovarian cancer, ovarian disorder, ovarian germ cell tumor, ovarian mucinous adenocarcinoma, ovarian squamous cell carcinoma, ovarian transitional cell carcinoma, pancreas disorder, pancreatic acinar cell carcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paraganglioma, paranasal sinus carcinoma, paranasal sinus disorder, paranasal sinus neoplasm, parathyroid gland carcinoma, parathyroid gland disorder, peripheral nervous system disorder, peripheral nervous system neoplasm, pheochromocytoma, placental choriocarcinoma, pregnancy disorder, primitive neuroectodermal tumor, pseudomyxoma peritonei, respiratory system disorder, respiratory tract neoplasm, sarcoma, scrotum squamous cell carcinoma, seminal vesicle adenocarcinoma, seminoma, small intestine adenocarcinoma, somatostatinoma, spindle cell neoplasm, squamous cell carcinoma of penis, squamous cell carcinoma of the small intestine, testicular non-seminomatous germ cell tumor, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, trachea carcinoma, transitional cell carcinoma, trophoblastic neoplasm, undifferentiated carcinoma of esophagus, undifferentiated carcinoma of nasopharynx, undifferentiated carcinoma of stomach, ureter adenocarcinoma, ureter squamous cell carcinoma, urethra adenocarcinoma, urethra squamous cell carcinoma, vaginal adenocarcinoma, vascular cancer, vulva cancer, vulvar carcinoma, vulvar disease | Active, not recruiting | Phase 2 | 2026-06-17 | NCT02834013 | |
| Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Active, not recruiting | Phase 3 | 2026-06-09 | NCT02785952 | |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Previously Treated Non-Small Cell Lung Cancer | Recruiting | Phase 2 / Phase 3 | 2026-05-18 | NCT03851445 | |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02488967 | |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8 | Recruiting | Not applicable | 2026-04-02 | NCT03723928 | |
| S0820, Adenoma and Second Primary Prevention Trial | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2026-04-02 | NCT01349881 | |
| An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Not stated | 2026-03-13 | NCT05364086 | |
| A Study of miRNA 371 in Patients With Germ Cell Tumors | Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, germinoma, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, seminoma, testicular cancer, testicular disorder | Active, not recruiting | Not stated | 2026-03-12 | NCT04435756 | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-10 | NCT01674140 | |
| Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2025-12-19 | NCT02201992 | |
| Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2025-12-05 | NCT04625647 | |
| Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2025-05-07 | NCT04068103 |